Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF (V600E) by synergistically decreasing global trimethylation of H3K27

Clinical efficacy of differentiation therapy with mitogen‐activated protein kinase inhibitors (MAPKi) for lethal radioiodine‐refractory papillary thyroid cancer (RR‐PTC) urgently needs to be improved and the aberrant trimethylation of histone H3 lysine 27 (H3K27) plays a vital role in BRAF (V600E)‐M...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Hao, Cheng, Lin, Sa, Ri, Jin, Yuchen, Chen, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131946/
https://www.ncbi.nlm.nih.gov/pubmed/31970877
http://dx.doi.org/10.1111/jcmm.15007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131946/
https://www.ncbi.nlm.nih.gov/pubmed/31970877
http://dx.doi.org/10.1111/jcmm.15007

Ejemplares similares